ID   SK-MEL-33
AC   CVCL_6033
SY   SK-Mel-33; AZ-Mel
DR   Cosmic; 923387
DR   Wikidata; Q54954086
RX   DOI=10.1007/978-1-4615-7228-2_39;
RX   PubMed=1067619;
RX   PubMed=2983346;
RX   PubMed=3518877;
RX   PubMed=6864164;
RX   PubMed=6933476;
RX   PubMed=8432869;
CC   From: Memorial Sloan Kettering Cancer Center; New York; USA.
CC   Sequence variation: Mutation; HGNC; 914; B2M; Simple; p.Asp96Metfs*6 (c.286delG); Zygosity=Unspecified (PubMed=8432869).
CC   Derived from site: Metastatic; Axillary lymph node; UBERON=UBERON_0001097.
DI   NCIt; C3224; Melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   76Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 29-06-23; Version: 18
//
RX   DOI=10.1007/978-1-4615-7228-2_39;
RA   Houghton A.N., Oettgen H.F., Old L.J.;
RT   "Malignant melanoma. Current status of the search for melanoma-specific
RT   antigens.";
RL   (In) Immunodermatology. Comprehensive Immunology, Vol 7; Safai B., Good R.A. (eds.); pp.557-576; Springer; Boston (1981).
//
RX   PubMed=1067619; DOI=10.1073/pnas.73.9.3278;
RA   Carey T.E., Takahashi T., Resnick-Silverman L.A., Oettgen H.F.,
RA   Old L.J.;
RT   "Cell surface antigens of human malignant melanoma: mixed
RT   hemadsorption assays for humoral immunity to cultured autologous
RT   melanoma cells.";
RL   Proc. Natl. Acad. Sci. U.S.A. 73:3278-3282(1976).
//
RX   PubMed=2983346; DOI=10.1073/pnas.82.5.1470;
RA   Dracopoli N.C., Houghton A.N., Old L.J.;
RT   "Loss of polymorphic restriction fragments in malignant melanoma:
RT   implications for tumor heterogeneity.";
RL   Proc. Natl. Acad. Sci. U.S.A. 82:1470-1474(1985).
//
RX   PubMed=3518877; DOI=10.3109/07357908609038260;
RA   Fogh J.;
RT   "Human tumor lines for cancer research.";
RL   Cancer Invest. 4:157-184(1986).
//
RX   PubMed=6864164; DOI=10.1084/jem.158.1.53;
RA   Houghton A.N., Brooks H., Cote R.J., Taormina M.C., Oettgen H.F.,
RA   Old L.J.;
RT   "Detection of cell surface and intracellular antigens by human
RT   monoclonal antibodies. Hybrid cell lines derived from lymphocytes of
RT   patients with malignant melanoma.";
RL   J. Exp. Med. 158:53-65(1983).
//
RX   PubMed=6933476; DOI=10.1073/pnas.77.7.4260;
RA   Houghton A.N., Taormina M.C., Ikeda H., Watanabe T., Oettgen H.F.,
RA   Old L.J.;
RT   "Serological survey of normal humans for natural antibody to cell
RT   surface antigens of melanoma.";
RL   Proc. Natl. Acad. Sci. U.S.A. 77:4260-4264(1980).
//
RX   PubMed=8432869; DOI=10.1172/JCI116249;
RA   Wang Z., Cao Y., Albino A.P., Zeff R.A., Houghton A.N., Ferrone S.;
RT   "Lack of HLA class I antigen expression by melanoma cells SK-MEL-33
RT   caused by a reading frameshift in beta 2-microglobulin messenger
RT   RNA.";
RL   J. Clin. Invest. 91:684-692(1993).
//